000989.SHE Jiuzhitang Co Ltd
- Market cap
- CNY 7.16B
- P/E
- 19.0x
- P/B
- 1.87x
- ROE
- 10.8%
- Dividend yield
- 3.54%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000989.SHE undervalued?
Graham number000989.SHE trades 25.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiuzhitang Co Ltd fundamental analysis
No fundamental analysis for Jiuzhitang Co Ltd yet.
Jiuzhitang Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiuzhitang Co Ltd
Jiuzhitang Co., Ltd. provides traditional Chinese, chemical, biological, and health medicine products in China. It offers Shuxuetong injections, Angong Niuhuang pills, Tianma Gouteng granules, Danxi granules, and Compound Lipid-Reducing tablets for cardiovascular and neurological treatment; Nude Flower Zizhu tablets, Xiaojin pills, Guizhi Fuling pills, Buxue Shengru granules, and Zhixue Zhentong capsules for gynecological treatment; Houyan pills for ear, nose, and throat (EN…
Full company profileJiuzhitang Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiuzhitang Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.67B | 3.84B | 3.16B | 3.18B | 3.56B | 3.78B | 3.03B | 2.96B | 2.37B | 2.21B | 2.92B |
| Gross Profit | 1.60B | 2.63B | 1.96B | 1.95B | 2.14B | 2.22B | 1.77B | 1.79B | 1.39B | 1.25B | 1.74B |
| Operating Income | 737M | 834M | 383M | 269M | 351M | 366M | 454M | 350M | 251M | 247M | 628M |
| EBITDA | 867M | 949M | 502M | 366M | 462M | 479M | 579M | 474M | 367M | 374M | 670M |
| Net Income | 652M | 721M | 336M | 192M | 272M | 271M | 358M | 297M | 216M | 223M | 405M |
| EPS | 0.75 | 0.83 | 0.39 | 0.23 | 0.32 | 0.32 | 0.42 | 0.35 | 0.25 | 0.26 | 0.47 |
| Balance Sheet | |||||||||||
| Total Assets | 4.80B | 5.87B | 5.25B | 4.90B | 5.07B | 5.27B | 5.24B | 5.33B | 5.21B | 5.44B | 5.52B |
| Total Liabilities | 660M | 1.37B | 937M | 913M | 1.15B | 1.30B | 1.26B | 1.38B | 1.26B | 1.29B | 1.27B |
| Shareholders' Equity | 4.14B | 4.50B | 4.30B | 3.99B | 3.92B | 3.97B | 3.99B | 3.95B | 3.75B | 3.72B | 3.73B |
| Cash & Short-term Investments | 1.56B | 840M | 546M | 851M | 1.10B | 808M | 1.09B | 904M | 893M | 912M | 595M |
| Total Debt | 619K | - | - | - | 102M | 106M | 86.6M | 124M | 51.5M | 136M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 612M | 152M | 426M | 851M | 610M | 366M | 499M | 121M | 199M | 438M | - |
| Capital Expenditure | 72.8M | 124M | 142M | 151M | 80.9M | 207M | 96.8M | 72.8M | 72.2M | 40.0M | 101M |
| Free Cash Flow | 540M | 28.4M | 284M | 700M | 529M | 159M | 402M | 35.8M | 127M | 398M | 669M |
| Ratios | |||||||||||
| ROE | 15.8% | 16.0% | 7.8% | 4.8% | 6.9% | 6.8% | 9.0% | 7.5% | 5.8% | 6.0% | 10.8% |
| ROA | 13.6% | 12.3% | 6.4% | 3.9% | 5.4% | 5.1% | 6.8% | 5.6% | 4.1% | 4.1% | 7.3% |
| Net Profit Margin | 24.4% | 18.8% | 10.6% | 6.0% | 7.7% | 7.2% | 11.8% | 10.0% | 9.1% | 10.1% | 13.9% |
| Debt to Equity | 0.00x | - | - | - | 0.03x | 0.03x | 0.02x | 0.03x | 0.01x | 0.04x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiuzhitang Co Ltd dividends
- Dividend yield
- 3.54%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 114.1%
- Ex-dividend date
- May 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 254M | 0.30 | 114.1% |
| 2024 | CNY 339M | 0.40 | 156.6% |
| 2023 | CNY 342M | 0.40 | 115.1% |
| 2022 | CNY 342M | 0.40 | 95.6% |
| 2021 | CNY 342M | 0.40 | 126.5% |
| 2020 | CNY 336M | 0.40 | 123.4% |
| 2019 | CNY 336M | 0.40 | 174.9% |
| 2018 | CNY 348M | 0.40 | 103.3% |
| 2017 | CNY 348M | 0.40 | 48.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 11.5:10 on May 27, 2016.
Who owns Jiuzhitang Co Ltd
- Insiders 44.60%
- Institutions 2.02%
- Public & others 53.38%
- Shares outstanding 856M
- Free float 449M
Jiuzhitang Co Ltd company profile
- Company name
- Jiuzhitang Co Ltd
- Ticker
- 000989.SHE
- ISIN
- CNE000001394
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 9, 2000
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,674
- Fiscal year end
- December
- Address
- Chaoyang Sports Center, Beijing, China, 100026
- Phone
- 86 10 8468 3155
- Website
- hnjzt.com
About Jiuzhitang Co Ltd
Jiuzhitang Co., Ltd. provides traditional Chinese, chemical, biological, and health medicine products in China. It offers Shuxuetong injections, Angong Niuhuang pills, Tianma Gouteng granules, Danxi granules, and Compound Lipid-Reducing tablets for cardiovascular and neurological treatment; Nude Flower Zizhu tablets, Xiaojin pills, Guizhi Fuling pills, Buxue Shengru granules, and Zhixue Zhentong capsules for gynecological treatment; Houyan pills for ear, nose, and throat (ENT) diseases; Jianwei Yuyang tablets for digestion; and prescription drug product systems, Jiaxi Ganxian granules, and Chidan Tuihuang granules for liver diseases. The company also provides over-the-counter (OTC) drugs comprising blood-tonifying, cardiovascular and cerebrovascular, urinary system, pediatric, gynecologic, bone and muscles, respiratory system, dermatologic, nervous system, ENT, and digestive system products, and stem cell and other drugs. Jiuzhitang Co., Ltd. was founded in 1999 and is headquartered in Beijing, China.
Jiuzhitang Co Ltd management
7- Mr. Li Zhen GuoVice Chairman & General Manager · born 1960
- Mr. Lubao ZhouCFO & Head of Accounting · born 1978
- Mr. Chenxiao HanBoard Secretary · born 1986
- Mr. Yansong GaoDeputy General Manager · born 1982
- Ms. Chunfeng LiuDeputy General Manager · born 1963
- Mr. Yongsheng WuDeputy General Manager · born 1984
- Mr. Liangbin ZhangDeputy General Manager · born 1981